Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8136557 | 0.86 | ALDH1A1 (0.76) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL3142640 | 0.84 | MAPT (0.72) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7806842 | 0.82 | MAPT (0.69) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7249247 | 0.82 | ALDH1A1 (0.69) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL11404428 | 0.81 | ALDH1A1 (0.69) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL86392 | 0.81 | MAPT (0.67) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL29375440 | 0.81 | MAPT (0.67) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL8798148 | 0.81 | ALDH1A1 (0.68) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL7820863 | 0.81 | ALDH1A1 (0.68) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL8797223 | 0.81 | MAPT (0.68) | MAPTALDH1A1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2286811-A1 | Chemokine receptor antagonists and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1204665-B1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARM INC (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| US-6329385-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, VIRAL DISEASES AND GASTROINTESTINAL DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-0685478-B1 | QUINOLINE DERIVATIVES | UBE INDUSTRIES (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5591752-A | LEUKOTRIENE ANTAGONIST, ANTIALLERGEN, ANTIINFLAMMATORY AGENT, DIBENZ(B,E)OXEPINE | UBE INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| EP-0685478-A1 | QUINOLINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-4889858-A | ANTIHYPOXIC AGENTS, ANTICONVULSANTS, LIPID PEROXIDATION INHIBITORS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-12-26 | — | — | US | disclosed |
| EP-0269755-A1 | DIBENZ b,e OXEPIN DERIVATIVE AND PHARMACEUTICAL CONTAINING THE SAME AS ACTIVE INGREDIENT | Dainippon Pharmaceutical Co., Ltd. (JP) | 1988-06-08 | — | — | EP | disclosed |
| US-4448786-A | TREATMENT AND PREVENTION OF CALCIUM OXALATE KIDNEY STONES | MERCK & CO., INC. (US) | 1984-05-15 | — | — | US | disclosed |
| US-4349561-A | 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase | MERCK & CO., INC. (US) | 1982-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119973-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | CCL11, ACKR3, CXCR4 | MAPT 4707/4885ALDH1A1 1533/4885RAB9A 2658/4885 |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | MAPT 4720/4885ALDH1A1 2010/4885RAB9A 2306/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | MAPT 4776/4885ALDH1A1 2146/4885RAB9A 1928/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | MAPT 4776/4885ALDH1A1 2146/4885RAB9A 1928/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | MAPT 4776/4885ALDH1A1 2146/4885RAB9A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.